glp-1 nad Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Microdosed GLP-1 (Semaglutide)

Semaglutide has received FDA approval for cardiovascular event risk reduction in 2020 and, most recently, kidney disease risk reduction in 2025 [14, 15, 3032]

Hartcoherentie is ook wetenschappelijk onderbouwd

However, these technologies are years away from potential approval for human use

GLP-1 receptors are present not only in the pancreas and gastrointestinal tract but also in the central nervous system , including areas involved in taste perception and appetite regulation

In Glucagon III (Handbook of Experimental Pharmacology, 123) (ed

GLP-1RAs stimulate insulin secretion in a glucose-dependent manner, therefore, reduce the risk of hypoglycemia